Clinical Trial Update: Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fulvestrant with or without lapatinib and/or aromatase inhibitors for metastatic breast cancer after AI therapy; current status is UNKN…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Aromasin (exemestane)
• FEMARA (letrozole)
• Faslodex (fulvestrant)
• Tykerb (lapatinib)

Snippet

Sponsor: Gruppo Italiano Mammella (GIM) | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN